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The association between chromosomal radiosensitivity and cancer
predisposition has been clearly demonstrated in a number of heri-
table conditions (Sanford et al, 1989). This was first established
for patients with the recessively-inherited multi-system disorder
ataxia-telangiectasia (A-T) (Taylor, 1983) and further demon-
strated in 20 other inherited cancer-prone conditions (Scott et al,
1996, 1999). 
Scott et al (1994) reported that, using peripheral blood lympho-
cytes stimulated with phytohaemagglutinin (PHA) in vitro, they
could discriminate between A-T heterozygotes and normal controls
according to the number of chromatid aberrations induced by low
doses of radiation (the G2 assay). They demonstrated that 42% of
untreated breast cancer patients but only 9% of controls exhibit a G2
sensitivity similar to that of A-T heterozygotes (Scott et al, 1994,
1998). Three other groups have confirmed these findings in breast
cancer patients (Parshad et al, 1996; Patel et al, 1997; Terzoudi
et al, 2000). 
Increased chromosomal radiosensitivity among blood relatives
of breast cancer patients with high G2 scores have also been
demonstrated. Clear evidence of Mendelian heritability of G2
chromosomal radiosensitivity was established by Roberts et al
(1999). A single major gene could account for 82% of the variance
between family members. This strongly supports the view that
enhanced radiosensitivity of peripheral blood lymphocytes is a
marker for breast cancer-predisposing genes of limited penetrance. 
It is well established that breast cancers arising in carriers of the
breast cancer susceptibility genes, BRCA1 and  BRCA2 have
different histological characteristics from each other and from
breast cancers arising in patients unselected for family history
(Lakhani et al, 1997; 1998). A substantial proportion of families
with multiple breast cancers, however, are not attributable to these
two genes BRCA1 and BRCA2 (Peto et al, 1999). The pathological
characteristics of tumours arising in non-BRCA1 or non-BRCA2
families are different from BRCA1 and BRCA2 tumours (Lakhani
et al, 2000). There is also evidence that the pathological character-
istics of non BRCA1/BRCA2 familial breast cancers differ from
sporadic (nonfamilial) breast cancers (Lakhani et al, 2000). 
In breast cancer, a reliable indicator of prognosis has been
developed, the Nottingham Prognostic Index (Galea et al, 1992),
using information on tumour size, histological grade and nodal
status (see Table 2 for formula). 
No studies have compared the characteristics of breast cancers
in groups identified by their G2RS. We have therefore undertaken
such a study. 
MATERIALS AND METHODS 
Patients blood samples and clinical data
Peripheral venous blood was collected from 65 unselected hospital
outpatients with primary breast cancer at the time of attendance for
diagnosis and from 66 control surgical outpatients without malig-
nancy. The blood samples (10 ml) were collected into lithium
heparin tubes and transported at room temperature by car to the
St Andrews laboratory (a distance of 20 miles). Age, menstrual
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classification of tumour, histological grade and oestrogen receptor
status were documented retrospectively for the breast cancer
patients. Pathological assessment of tumours and oestrogen
receptor status, recorded by standard protocols by a specialist
breast pathologist, were undertaken independently of the G2 assay.
Results were collated after chromatid breaks were scored and were
not known to those carrying out the G2 assay. 
All of the studies were undertaken with ethical approval from
the Tayside and Fife Committees on Medical Research Ethics
(218/97 and DE/JRW20069717). 
G2 assay 
The blood samples were held in the laboratory overnight at room
temperature and set up for culture the following day. Two samples
were set up from each subject by adding 1 ml of blood to 9 ml
prewarmed and gassed medium (RPMI 1640 containing 10% FCS,
l-glutamine and antibiotics) to a 25 cm3 flask. PHA (Murex HA15,
150 µ l of the 5 ml stock) was added to each sample. The flasks
were placed flat in a humidified and gassed incubator (5%
CO2/95% air) for 72 h. 
At this time one flask was exposed to 0.4 Gy gamma irradiation
from a caesium 137 gamma source (IBL437C). The other sample
was mock irradiated. After 30 min incubation, colcemid (150 µ l of
10 µ g/ml stock) was added to each flask and returned to the incu-
bator for a further 1 h. The cells and medium were then transferred
to a 10 ml centrifuge tube and held on ice for 10 min. Cells were
treated with ice-cold hypotonic solution (0.075M KCI) for 10 min,
fixed and metaphase preparations made using standard protocols.
Slides were coded for scoring blind and 50–100 metaphase
spreads scored for aberrations under 63× oil immersion lens. The
number of chromatid breaks per 100 metaphases was determined:
the ‘G2 score’. 
Statistical analysis 
For comparisons between the G2 scores in breast cancer patients and
controls, the Mann-Whitney test was applied. The proportions of
patients and controls in the high G2RS group were estimated using
the 90th percentile of the control group as the cut-off, as described by
Scott et al (1999). Differences in the proportions in this high G2RS
cohort were compared for the breast cancer patients and controls
using the two-tailed Fisher’s exact test. Two groups of breast cancer
patients were further selected on the basis of their G2 lymphocyte
scores; 21 patients with the highest and 20 with the lowest G2 scores.
Comparisons between the patients in the high G2RS group and the
low G2RS group for oestrogen receptor positivity, nodal involvement
and menopausal status were undertaken using a χ 2 test. 
Comparisons of the median age and tumour diameter in these
two groups used the Mann-Whitney test. 
RESULTS 
Reproducibility of the G2 assay 
Independent repeat assays on 7 donors allowed an estimate of the
G2 assay reproducibility (intra-individual variance) which gave a
coefficient of variation (CV) of 8% compared with a CV of 19%
for inter-individual differences between donors. Assays on blood
collected at St Andrews and Dundee from the same donors on the
same day enabled samples to be checked for possible differences
introduced by the transport procedure. No differences were
detected. The correlation coefficient was 0.76 (P < 0.05). 
Comparison of the G2 scores in breast cancer patients
and hospital controls 
Figure 1 illustrates the distribution of G2 scores for patients and
controls. The mean overall G2 score for the breast cancer patients
(84.8 ± 36.8) was greater than that for the control group (63.3 ±
18.5) (Table 1, P < 0.0001). The median values were significantly
different (P < 0.0001). Using the 90th percentile of the control
group as the cut-off point, the proportion of breast cancer patients
with high G2 sensitivity was 46.2% compared to 13.6% for the
controls (since scores were in bins, 13.6% approximates the
closest to the 90th percentile). These proportions were signifi-
cantly different (P < 0.001) indicating that there was a substantial
sub-group of breast cancer patients exhibiting increased lympho-
cyte radiation sensitivity (Table 1). 
Comparison of the Nottingham Prognostic Index in
breast cancer patients exhibiting high or low G2 scores 
For the breast cancer patients, those in the highest and lowest
tertiles of G2, scores were grouped using the 3 lowest and the 7
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Table 1 Mean G2 scores (number of chromatid aberrations per 100
metaphases scored in peripheral blood lymphocytes), population standard
deviations, ranges and proportions of sensitive breast cancer patients and
normals in the G2 assay 
Normals Breast cancer patients 
Mean G2 score ± SD 63.6 ± 18.5 84.8 ± 26.8 P < 0.0001a
Range 24 – 118 42 – 181 
Sensitive sub-group 9/66 (13.6%)c 30/65 (46.2%)c P < 0.001b
Number of subjects 66 65 
Median age 47 58 
Range 20 – 76 29 – 95 
aMann-Whitney U test; bTwo-tailed Fisher’s exact test; cThe 90th percentile
was selected as the cut-off (as results were grouped in bins, more than 10%
of patients had scores equal to, or greater than, this figure). 
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Figure 1 Comparison of the G2 scores (number of chromatid breaks per
100 metaphases) measured in irradiated peripheral blood lymphocytes from
breast cancer patients and hospital outpatient controls (........90th percentile
cut-off from the control population)highest blocks of scores from the histogram (Figure 1). The
Nottingham Prognostic Index (NPI) was calculated using data on
the size of the primary tumour, axillary lymph node status and
histological grade (Table 2). The 15-year survival is related to the
NPI and can be used to define three sub-groups; a good prognosis
group (GPG: NPI < 3.4) with an 80% 15-year survival, a medium
prognosis group (MPG: NPI 3.4–5.4) with a 42% 15-year survival
and a poor prognosis group (PPG: NPI > 5.4) with a 13% 15-year
survival. In the Nottingham study (Galea et al, 1992), the propor-
tions of patients presenting in each sub-group were GPG 29%,
MPG 54% and PPG 17%. In our total unselected Tayside cohort,
the proportions were similar; GPG 27%, MPG 51% and PPG 22%
(χ 2 = 0.65; P ~ 0.5) (Figure 2). However, when the breast cancer
patients were separated into high and low G2RS groups, the
proportions changed markedly; GPG 15%, MPG 45% and PPG
40% in the low G2RS group compared to GPG 38%, MPG 57%
and PPG 5% in the high G2RS group (Figure 2). In both cases these
proportions were significantly different from those of the total
unselected cohort (low G2, χ 2 = 4.13, P < 0.05; high G2, χ 2 = 3.98,
P < 0.05). 
Comparison of the tumours and patients in the high
and low G2RS groups 
The tumours observed in the low G2RS group were all invasive ductal
carcinomas whereas in the high G2RS group there were two lobular
carcinomas and one tubulo-lobular type. There were no significant
differences between the low and high G2RS groups in the median
ages of the patients (P~ 0.3), the menopausal status (χ 2= 1.2, P> 0.1)
and the histological nodal status (χ 2 = 0.22, P > 0.5) (Table 3). 
Both the median tumour diameter (P < 0.001) and the propor-
tion of oestrogen receptor positive tumours (P < 0.05) were signi-
ficantly different in the two groups. The low G2RS group tended to
have larger tumours which were oestrogen receptor negative
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Table 2 Comparison of the age, G2 score, tumour diameter, stage, grade and the Nottingham Prognostic Index for two cohorts of breast cancer
patients with a high or a low G2 score 
Age (years) G2 score Tumour diameter Stage Grade Nottingham 
(cm) Prognostic 
Indexa
Low G2 scores 53 47 2.2 2 3 5.44 
45 46 3.0 2 3 5.60 
58 52 1.5 1 1 2.30 
50 42 4.5 2 2 4.90 
55 50 2.5 2 3 5.50 
32 54 1.8 1 3 4.36 
29 58 2.0 1 3 4.40 
57 63 2.5 1 2 3.50 
41 62 1.3 2 2 4.26 
60 64 3.1 1 2 3.62 
50 64 2.0 1 3 4.40 
69 66 2.3 2 2 4.46 
77 64 2.7 3 3 6.54 
55 62 2.0 1 2 3.40 
64 60 1.2 1 2 3.24 
60 64 3.6 3 3 6.72 
69 62 3.5 3 3 6.70 
55 60 2.2 3 3 6.44 
67 66 2.6 1 2 3.52 
84 56 3.0 2 3 5.60 
High G2 scores 60 181 0.8 2 2 4.16 
66 115 1.5 2 3 5.30 
77 113 1.8 1 2 3.36 
62 120 1.4 1 2.5 3.76 
49 106 2.0 1 2 3.40 
58 114 1.5 1 3 4.30 
51 126 1.0 1 2 3.20 
60 107 2.0 3 2 5.40 
53 125 1.1 1 3 4.22 
70 105 1.5 1 3 4.30 
53 101 1.7 2 1 3.34 
37 116 2.0 2 3 5.40 
35 110 2.0 2 1 3.40 
60 96 2.1 2 2 4.42 
56 96 1.2 1 1.5 2.74 
82 92 1.5 1 3 4.30 
95 92 2.8 1 2 3.56 
83 92 1.4 1 2 3.28 
54 138 1.7 1 2 3.34 
73 104 1.6 3 2 5.32 
59 112 1.5 3 3 6.30 
aThe Nottingham Prognostic Index (Galea et al, 1992) = histological grade + stage + (tumour diameter cm × 0.2). whereas the high G2RS group had tumours that were smaller and
oestrogen receptor positive (Table 3). 
A predicted 15-year survival can be calculated from the propor-
tions of patients in each sub-group as indicated by the NPI. For the
high G2RS group this was 55% compared to 36% for the low G2RS
group. For the total unselected cohort, the predicted 15-year survival
would be 46% (Table 3). 
DISCUSSION 
We have confirmed that a significant proportion of breast cancer
patients exhibit an elevated G2RS value relative to controls. The
proportion of radiosensitive patients observed in the Tayside
cohort (46.2%) was similar to that reported in the Manchester
studies (42%, Scott et al, 1994; 39% Scott et al, 1999; χ 2 corr =
0.6, P ~ 0.4). These figures are consistent with data from epidemi-
ological studies suggesting a substantial frequency of low pene-
trance genetic predisposition to breast cancer (Teare et al, 1994;
Chen et al, 1995; Houlston and Peto, 1996). Increased chromosomal
radiosensitivity has also been reported in breast cancer patients by
Patel et al (1997), Terzoudi et al (2000) and Parshad et al (1996)
although the numbers studied in these series do not permit close
comparison of the proportions showing increased radiosensitivity. 
Assay reproducibility between and within donor groups was
similar to that previously reported (Scott et al, 1999). Problems
with transport of blood samples were not encountered presumably
because of the proximity of the centres in this study. 
High lymphocyte G2RS appears to be unrelated to sex, age or to
environmental variables. There is now clear evidence that
radiosensitivity, as measured by the G2 assay, in breast cancer
patients is inherited and likely to be a marker for a small number
of low penetrance genes predisposing to breast cancer (Roberts
et al, 1999). Thus from our data and those of Scott et al
(1994;1999), women with a high G2RS genotype are at approxi-
mately five-fold greater risk than those with a normal G2RS: i.e.
penetrance of this trait with respect to breast cancer is estimated at
approximately 35%. Hence this heritable characteristic accounts
for some 30% of all breast cancer cases, at least six times as many
as all other currently recognized forms of heritable breast cancer
combined. Patients in this study were not selected on the basis of
family history and, given the estimated low penetrance of the
cancer trait, detailed analysis of extended family trees would be
required to demonstrate heritability. 
The Nottingham Prognostic Index has proved useful in
predicting survival in breast cancer patients and has been assessed
prospectively (Galea et al, 1992; Brown et al, 1993; Balslev et al,
1994). The proportions of the three prognostic sub-groups in our
cohort of unselected breast cancer patients were similar to those
reported in the much larger study from Nottingham (Galea et al,
1992). However, when subdivided on the basis of the G2 score, the
results were quite different and patients in the low G2RS group had
a much poorer predicted prognosis than those in the high G2RS
group. This difference could not be explained on the basis of age
or menopausal status. In fact rather more patients in the low G2RS
group were post-menopausal. 
Several properties of the tumours in the low and high G2RS
groups showed distinct differences. In the high G2 sensitive group,
the tumours tended to be not only smaller at presentation but also
oestrogen receptor positive. This would lead to a further improve-
ment in prognosis for the high G2RS group, compared to the low
G2RS group. Taking into account that the 15-year survival in age
matched cancer-free controls is 83% then a predicted improvement
from 36% to 55% 15-year survival in the low versus the high
G2RS group represents a dramatic difference. 
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80% 15-year survival; GPG, NPI < 3.4
42% 15-year survival; MPG, NPI 3.4 – 5.4
13% 15-year survival; PPG, NPI > 5.4
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Figure 2 Comparison of the percentage of breast cancer patients in each
category defined by the Nottingham Prognostic Index (Galea et al, 1992).
(A) Comparison of unselected breast cancer patients from Nottingham and
Tayside. (B) Breast cancer patients from the Tayside group selected on the
basis of high and low G2 score 
Table 3 Characteristics of patients and tumours in the high G2 sensitivity group and the low G2 sensitivity
group 
High G2
a
sensitivity Low G2
a
sensitivity 
n = 21 n = 20 
Median age (range) 60 (30–95) 56 (29–84) P ~0.3b
Mean G2 score (breaks per 100 metaphases) 112 ± 4 58 ± 2 
Oestrogen receptorc % +ve 81 45 P < 0.05d
Median tumour diameter (cm) 1.5 2.4 P < 0.001b
Histological nodal status (% +ve) 43 55 P > 0.5c
Menopausal status (% postmenopausal) 65 85 P > 0.1c
Predicted 15-year survival (%) 55 36 
aHighest and lowest tertile of the observed range; bMann-Whitney U test; cOestrogen receptor status
defined using standard immunocytochemical methods using quick score analysis; dχ 2 test.The above features of the tumours in the high G2RS cohort are
distinct from those associated with other hereditary forms of breast
cancer notably those accompanying germline mutations in
BRCA1 or BRCA2. However, the characteristics of the non
BRCA1 / BRCA2 familial tumours reported recently are similar to
those found by us in the high G2RS group (Lakhani et al, 2000).
The non BRCA1 / BRCA2 tumours were of lower grade indicating
presumably a more favourable prognosis. 
Only 3 tumours in the series were of ‘special type’ (2 lobular
carcinomas and 1 tubulo-lobular carcinoma). These tend to carry a
relatively good prognosis. All 3 were in the high G2RS group. One
previous report found no significant difference in G2RS according
to tumour grade (Scott et al, 1999). However there was also some
evidence that patients with larger tumours (T2 compared to T1)
had higher G2 scores (Scott et al, 1999) which is contrary to our
findings. That study was not designed specifically to examine the
issue of tumour characteristics and detailed analysis of the findings
was not reported. 
The possible mechanisms underlying G2RS and the identity of
the low penetrance genes involved in cancer predisposition have
not yet been established but it seems likely that chromatid breaks
arise by a process involving genomic rearrangements (Bryant,
1998; Rogers-Bald et al, 2000). The cellular response to DNA
damage is regulated by a network of proteins. Following the
induction of double-stranded breaks in chromosomal DNA, a
complex network is activated that regulates DNA repair and
progression through the cell cycle (Wang, 2000). Genes in this
network protect the integrity of the genome and mutational events
in these genes can predispose individuals to cancer. According to
one scheme, cancer susceptibility genes can be conveniently clas-
sified into two groups: gatekeepers and caretakers (Kinzler and
Vogelstein, 1997). Gatekeeper genes are important in cell cycle
control and apoptosis. Caretaker genes are involved in DNA repair
and inactivation results in genetic instability. We hypothesise that
inactivation of caretaker genes influences the processing of DNA
damage and thus leads to increased chromatid damage (high
G2RS). The low penetrance gene/s involved in predisposition to
breast cancer might thus be members of the caretaker gene family. 
The differences that we have reported in this preliminary study
of patients with breast cancers in low and high G2RS groups,
would warrant a more detailed study on a larger cohort of breast
cancer patients to determine whether the high G2RS group do
indeed have an improved prognosis and comprise a distinct subset
for whom specific screening and management policies may be
appropriate. Our observations may also facilitate the identification
of the low penetrance genes involved. It would not be possible to
use the G2 assay as a population screening method for breast
cancer as it is technically demanding and time-consuming.
However if these low penetrance genes can be identified, then it
will be possible to determine whether specific polymorphisms
serve as markers for increased risk of breast cancer. 
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